Smartlab Europe

News

ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

ArisGlobal, the leading provider of life sciences software that automates core drug development functions with its end-to-end technology platform LifeSphere®, announces significant growth in the global footprint of its LifeSphere Clinical software, following the customer wins of two prominent...

CPHI North America opens as 65% of US companies forecast growth in excess of 20% in 2022

Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May, 2022) as well as in-person (17-19 May, 2022). CPHI North America will be held as a SMART event, with three weeks of dedicated pharma learning and partnering. The benefit for...

Sepha’s new EZ Blister+ enables 21 CFR Part 11 compliant micro-batches

Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities. The EZ Blister+ meets increased demand for 21 CFR Part 11 compliant...

Moderna Jab For Kids Upto 6 Years 44% Apt Against Omicron

According to the data presented by Moderna, the two-dose COVID vaccination was around 44% effective in preventing omicron infection in children aged 6 months to under 2 years, and about 38 percent effective in children aged 2 to 5. As...

COVID-19 Vaccine On Its Way To Becoming An Yearly Affair

Public health experts aren't sure what the future has in store for COVID-19 immunizations, but some think it's becoming increasingly likely that these doses will be required on an annual basis, similar to the way flu shots are advised each...

Abzena Secures $65 Million in Additional Funding to Accelerate Growth and Expand Capacity

Abzena, a leading global contract development and manufacturing organization (CDMO) providing integrated discovery, development, and manufacturing of biologics and antibody drug conjugates (ADCs), announced a new round of investment. Funding sources for the additional $65 million include majority-owner Welsh,...

Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0.

Rokote Laboratories Finland Ltd., a vaccine development company focusing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials. Exothera will finetune the industrialization of the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »